Xencor INC 10-K annual reports

Xencor, a clinical-stage biopharmaceutical company, reported a net loss of $91.9 million in 2025, driven by increased R&D, while advancing multiple oncology and autoimmune drug candidates and remediating prior material weaknesses in internal controls.

Xencor's 2024 10-K filing highlights a strategic focus on T-cell engaging bispecific antibodies, provides updates on its clinical pipeline, and outlines its financial position and future outlook.

Xencor restated its 2023 financial statements due to errors in royalty accounting and tax treatment, leading to the identification of material weaknesses in internal controls.

Xencor and Genentech have amended their collaboration agreement, transitioning from a cost-sharing model to a royalty and milestone-based structure effective June 1, 2024.